Arthritis, Rheumatoid  >>  andecaliximab (GS-5745)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
andecaliximab (GS-5745) / Gilead
RA POC, NCT02862574 / 2016-000897-39: Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis

Terminated
2
15
US
Andecaliximab, GS-5745, Placebo, Methotrexate, TNF Inhibitor
Gilead Sciences
Rheumatoid Arthritis
06/17
08/17

Download Options